NEW HAVEN, Conn. and SAN FRANCISCO, Jan. 8, 2024 /PRNewswire/ -- Biohaven Ltd. (BHVN) (Biohaven or the Company), a clinical-stage biopharmaceutical company focused on the discovery, development and ...
Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner’s National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback